Information Provided By:
Fly News Breaks for June 25, 2015
LLY
Jun 25, 2015 | 07:39 EDT
As previously reported, BofA/Merrill upgraded Eli Lilly to Buy from Neutral and added it to the US 1 List. The firm raised estimates and increased its price target to $101 from $74 based on more bullish pipeline expectations. BofA/Merrill highlights eva and sola pipelines, which have high risk/reward opportunities with Phase III data in the next 12-18 months. Firm forecasts peak sales of $1.5B for eva and $2B for sola and said success in either of these programs would result in significant upside to estimates.
News For LLY From the Last 2 Days
LLY
Mar 28, 2024 | 16:23 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
LLY
Mar 26, 2024 | 07:08 EDT
JPMorgan estimates Amgen (AMGN) without its obesity pipeline is worth $240-$250 per share and that the market is assigning $30-$40 per share of value to Maritide. While the competitive bar for Maritide is high and moving higher based on Novo Nordisk's (NVO) recent pipeline updates, the obesity market is also "unprecedented in terms of size," the analyst tells investors in a research note. The firm estimates peak sales for Maritide of $6B, equating to mid-single-digit share within the incretin space. JPMorgan believes this supports a value roughly in-line with what is reflected in Amgen's current share price. It sees a positive risk/reward scenario given the recent pullback but maintains a Neutral rating on the name with a $290 price target. The firm says Amgen is viewed as the best positioned name beyond Eli Lilly (LLY) and Novo to have a role in the obesity space.